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Quantitative computed tomographyIn the FREEDOM study, denosumab treatment (60 mg every 6 months) decreased bone resorption, increased
bonemineral density (BMD), and reducednewvertebral, nonvertebral, and hip fractures over 36 months in post-
menopausal women with osteoporosis. In a subset of these women, hip quantitative computed tomography
(QCT) was performed at baseline and months 12, 24, and 36. These scans were analyzed using Medical Image
Analysis Framework (MIAF) software, which allowed assessment of total hip integral, trabecular, subcortical,
and cortical compartments; the cortical compartment was further divided into 2 areas of interest (outer and
inner cortex). This substudy reports changes in BMD and bone mineral content (BMC) from baseline and
compared placebo with denosumab over 36 months of treatment (placebo N = 26; denosumab N = 36).
Denosumab treatment resulted in signiﬁcant improvements in total hip integral volumetric BMD (vBMD)
and BMC from baseline at each time point. At month 36, the mean percentage increase from baseline in total
hip integral vBMD and BMC was 6.4% and 4.8%, respectively (both p b 0.0001). These gains were accounted
for by signiﬁcant increases in vBMD and BMC in the trabecular, subcortical, and cortical compartments. In the
placebo group, total hip integral vBMD and BMC decreased at month 36 from baseline by −1.5% and −2.6%,
respectively (both p b 0.05). The differences between denosumab and placebo were also signiﬁcant at months
12, 24, and 36 for integral, trabecular, subcortical, and cortical vBMD and BMC (all p b 0.05 to b0.0001). While
the largest percentage differences occurred in trabecular vBMD and BMC, the largest absolute differences
occurred in cortical vBMD and BMC. In summary, denosumab signiﬁcantly improved both vBMD and BMC
from baseline and placebo, assessed by QCT MIAF, in the integral, trabecular, subcortical, and cortical hip com-
partments, all of which are relevant to bone strength.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Hill Road, Tiburon, CA 94920, USA. Fax: +1 415 366 2220.
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Dual-energy x-ray absorptiometry (DXA) remains the most widely
used technique to identify patients at risk for fracture and assess re-
sponse to osteoporosis therapy in the clinical setting. However, DXA is
a 2-dimensional measurement of areal bone mineral density (aBMD)
and is therefore limited in the assessment of bone geometry, and is
not able to fully distinguish the trabecular and cortical bone compart-
ments. Recent imaging and technical developments allow improved
in vivo evaluations of skeletal sites of clinical relevance in subjects at
risk for fracture. In particular, QCT advancements now enable precise
and detailed assessments within the trabecular and cortical bone com-
partments [1,2].
There is increasing evidence that both trabecular and cortical bone
are important determinants of strength in patients with osteoporosis
who experience fracture [3–6]. Assessing both trabecular and cortical
bone is important as these compartments may lose or gain bone differ-
ently with aging and in response to therapies, impacting their speciﬁc
relative contributions to bone strength [7–9]. The amounts of both
trabecular and cortical bone decrease as osteoporosis progresses; how-
ever, as trabecular bone disappearswith increasing bone loss, the extent
to which the cortical compartment contributes to bone strength in-
creases [8–10].
Use of new image acquisition and analysis techniques can provide
information on the effects of treatments on bone density and geometri-
cal changes in the trabecular and cortical compartments. Quantitative
computed tomography (QCT) complements DXA by 3-dimensionally
measuring volumetric BMD (vBMD) and bone mineral content (BMC),
commonly referred to as bone mass; these can be measured not only
within the total bone but also separately in the individual bone com-
partments [2,11].
Denosumab (Prolia®; Amgen Inc., Thousand Oaks, CA, USA) is a
fully human monoclonal antibody that inhibits RANKL, a key mod-
ulator of osteoclast formation, function, and survival [12–15]. The
mechanism of action of denosumab leads to rapid and maximal re-
ductions in bone resorption throughout the trabecular and cortical
compartments [16]. Clinical trials, including the FREEDOM (Fracture
REduction Evaluation of Denosumab in Osteoporosis every 6 Months)
study, have established that denosumab treatment results in a signiﬁ-
cant improvement in DXA aBMD at the hip in the majority of subjects
[17–23], and these gains signiﬁcantly explained the observed fracture
risk reductions [24].
Areal BMD gains are inﬂuenced by both trabecular and cortical
changes, which cannot be precisely distinguished with DXA. In view of
the strong association between gains in aBMD and the fracture risk
reductions observed with denosumab treatment, and that both tra-
becular and cortical bone determine whole-bone strength, we have
hypothesized andpreviously demonstrated using standardQCT analysis
software that total hip BMD changes associatedwith denosumabwould
be apparent in both the trabecular and cortical compartments [25]. To
further document and characterize the magnitude and distribution of
the changes in BMD and BMC at the hip, and understand the relative
contribution of each compartment, including the subcortical compart-
ment, we applied Medical Image Analysis Framework (MIAF) software
to hip QCT scans obtained in a subset of women who participated in
the FREEDOM study. MIAF improves the 3D segmentation of the hip,
and thus provides a more comprehensive method to evaluate integral
and compartment changes [26,27].
Methods
Study design and data source
FREEDOM was an international, multicenter, randomized, double-
blind, placebo-controlled study. Subjects were randomly assigned
to receive subcutaneous injections of either placebo or denosumab60 mg every 6 months for 36 months. All women received daily
supplementation of calcium (≥1000 mg) and vitamin D (≥400 IU).
The methods and results of the overall study have been previously
reported [20]. Study centers in the FREEDOM study with expertise
and access to a qualiﬁed QCT scanner invited subjects to participate
in a QCT substudy of the lumbar spine and hip measurements. The
methods and primary results of this QCT substudy have been report-
ed [25].
In this substudy of the FREEDOM study, hip QCT scans were used to
non-invasively further assess changes in hip vBMD and BMC associated
with placebo and denosumab treatment over 36 months.Participants
The FREEDOM study included postmenopausal women aged 60 to
90 years with a DXA BMD T-score of b−2.5 at either the lumbar spine
or total hip, and not b−4.0 at either site. Women were excluded if
they had any severe or N2 moderate vertebral fractures, had conditions
that affected bone metabolism, had taken oral bisphosphonates for
N3 years, or received intravenousbisphosphonates,ﬂuoride, or strontium
treatment for osteoporosis within the last 5 years. The protocol was
approved by an independent ethics committee or institutional review
board at each study site prior to study commencement. The study was
conducted in accordance with Good Clinical Practice and the Declaration
of Helsinki, and registered at ClinicalTrials.gov (NCT00089791).Assessments
QCT scans of the left hip were performed at 120 kV with a pitch
of 1 using 170 mAs, reconstructed using a 200 mm ﬁeld of view, a
slice thickness of 1 or 1.25 mm, and a medium kernel at baseline,
and at months 12, 24, and 36. QCT technicians were trained on the
techniques and procedures, including subject positioning and phantom
calibration scanning. Scanner stability and cross-calibrationwere longi-
tudinally assessed during the study. Scans were analyzed in a blinded-
to-treatment manner by a central laboratory (Synarc Inc., Newark, CA,
USA) and analyzed using MIAF software.
MIAF enables automated 3-dimensional segmentation of the hip,
dividing the proximal femur into anatomical and compartment regions.
In this study, the total hip volume of interest (VOI)was analyzed, which
is approximately equivalent to the total hip region of interest with DXA.
The QCT total hip integral VOI was segmented into trabecular, sub-
cortical, and cortical bone compartments (Fig. 1). The periosteal and
endosteal surfaces deﬁning the cortical compartment were segmented
as described previously [27]. Then the trabecular compartment was
obtained by a homogeneous 2 mm peeling process from the endosteal
surface. The selection of 2 mmpeelingwas based on phantommeasure-
ments to account for blurring artifacts introduced by the limited spatial
resolution of the CT scanner. The peeled volume was denoted as the
subcortical compartment and represents the transitional zone between
compact cortex and pure trabecular bone, a region that is thought
in this age group to correspond to cortical bone, which has been
“trabecularized” through endocortical and intracortical resorption.
To further explore the changes within the cortex, the segmented
cortical compartment was electronically partitioned into an outer and
an inner cortex, where the outer cortex covered two-thirds and the
inner cortex covered one-third of the total cortical thickness. For each
compartment, vBMD and volume were measured and BMC calculated
from the product of vBMD and volume.
To evaluate the consistency between QCT and DXA, changes at the
total hip using scans from Hologic, Inc. (Bedford, MA, USA; n = 57) or
GE Healthcare Lunar (Waukesha,WI, USA; n = 5) DXAmachines avail-
able from the subjects in the QCT study also were compared at baseline
and months 12, 24, and 36.
Fig. 1.HipQCT regions of interestwithMIAF software. Trabecular (red), subcortical (yellow),
and cortical (blue) compartments of the total hip volume of interest analyzed with MIAF
software. The total hip volume of interest includes the neck, trochanter, and intertrochanter.
MIAF, Medical Image Analysis Framework; QCT, quantitative computed tomography.
Table 1
Baseline characteristics.
Placebo
N = 26
Denosumab
N = 36
Age (years) 74.2 (6.1) 72.8 (4.7)
Ethnicity (n, %)
White/Caucasian 14 (53.8) 22 (61.1)
Black/African–American 1 (3.8) 0
Hispanic/Latino 11 (42.3) 14 (38.9)
BMI (kg/m2) 25.0 (3.9) 26.0 (4.9)
Creatinine clearance (mL/min) 60.5 (21.0) 64.3 (21.0)
Total hip integral vBMD (mg/cm3) 216 (31) 224 (34)
Total hip aBMD (g/cm2) 0.70 (0.1) 0.74 (0.1)
Total hip BMD T-score −2.1 (0.7) −1.7 (0.9)
Total hip BMC (mg) 15603 (3102) 16843 (2664)
Values are means (standard deviations) unless otherwise indicated.
aBMD, areal bone mineral density; BMI, body mass index; BMC, bone mineral content;
BMD, bone mineral density; vBMD, volumetric bone mineral density.
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Endpoints for this substudy included changes in total hip integral,
trabecular, subcortical, and cortical vBMD and BMC from baseline and
compared with placebo at months 12, 24, and 36. In addition, the outer
and inner cortex regions were assessed.
Statistical analysis
Subjects had to have a baseline scan and≥1 post-baseline scan ana-
lyzed by MIAF to be included in the analysis. Hip QCT scans at each
annual visit for each subject were included in the analyses. There was
no imputation of missing data. The percentage and absolute changes
from baseline for vBMD and BMC were determined. Data analyses
assessed changes over time relative to baseline for each treatment
group and also compared with placebo. The percentage and absolute
changes from baseline were analyzed using an analysis of covariance
(ANCOVA) model including treatment and adjusting for baseline value
and age strata (stratiﬁcation factor). Least-squares means and 95% con-
ﬁdence intervals (CIs) for each treatment and for the treatment differ-
ence (denosumab — placebo) at each time point were generated. All
analyses were exploratory and post hoc. P-values and CIs were not
adjusted for multiplicity.
Results
This substudy included 62 postmenopausal women with osteo-
porosis (placebo N = 26; denosumab N = 36). Subject demographics
were balanced between treatment groups (Table 1). Most women wereWhite/Caucasian (53.8% placebo; 61.1% denosumab), with a mean age
of 74.2 years in the placebo group and 72.8 years in the denosumab
group. Mean total hip integral vBMD was 216 mg/cm3 and 224 mg/cm3
for the placebo and denosumab groups, respectively, and mean total
hip aBMD was 0.70 g/cm2 for the placebo group and 0.74 g/cm2 for the
denosumab group. Mean total hip integral BMC as measured by QCT
was 15603 mg and 16843 mg for the placebo and denosumab groups,
respectively. At baseline, the proportion that each compartment contrib-
uted to BMCwas 69% for the cortical compartment, 18% for the trabecular
compartment, and 13% for the subcortical compartment. These propor-
tionswere similarwithin each treatment group, and remained consistent
at month 36.
Using QCT MIAF, denosumab treatment was shown to signiﬁ-
cantly increase total hip integral vBMD from baseline and compared
with placebo at months 12, 24, and 36. In the denosumab group, the
mean percentage change from baseline to month 36 in total hip inte-
gral vBMD was 6.4% (p b 0.0001; Fig. 2). In the placebo group, total
hip integral vBMD decreased over the same time interval by −1.5%
(p = 0.008). The treatment difference between denosumab and pla-
cebo was signiﬁcant at months 12, 24, and 36 (p b 0.01 for all). Inte-
gral volume of the total hip did not signiﬁcantly change in either
group (data not shown).
The BMD results were similar when assessed by DXA (Fig. 2). At
baseline, total hip integral vBMD and aBMD for all subjects showed a
strong correlation (r = 0.83; p b 0.0001; data not shown). Changes in
vBMD and aBMD during the study were moderately correlated in both
the placebo group (r = 0.47; p b 0.0001) and the denosumab group
(r = 0.32; p = 0.0004).
The percentage gains in total hip integral vBMD in the denosumab
groupwere accounted for by signiﬁcant increases in the trabecular, sub-
cortical, and cortical compartments at months 12, 24, and 36 (Fig. 3).
Within the cortical compartment, similar improvements were observed
in the outer and inner cortical regions (data not shown).
Denosumab treatment also signiﬁcantly increased total hip integral
BMC from baseline by month 12 (2.4%; p b 0.001), and the improve-
ment progressed over 36 months. Treatment with denosumab resulted
in a mean percentage change from baseline to month 36 in total hip
integral BMC of 4.8% (p b 0.0001), and treatment with placebo led to
a decrease of −2.6% over the same time interval (p = 0.0004; Fig. 4).
The treatment difference between denosumab and placebo was signiﬁ-
cant atmonths 12, 24, and 36 (p b 0.001 for all). Similar to observations
with total hip integral vBMD, a strong correlation also was observed at
baseline for these QCT MIAF total integral BMC measurements and
DXA BMC for all subjects (r = 0.88; p b 0.0001; data not shown).
Signiﬁcant percentage gains in BMC from baseline and compared
with placebo also were observed in the denosumab group in each
bone compartment, speciﬁcally the trabecular, subcortical, and cortical
Fig. 2. Integral BMD percentage changes from baseline assessed by QCTMIAF and DXA at the total hip. Least-squaresmeans, 95% conﬁdence intervals (CIs), and p-values from analysis of
covariance model are presented. ⁎p ≤ 0.002 compared with baseline and placebo; †p b 0.05 compared with baseline; ‡p b 0.05 compared with month 12. Month 12, n = 60; month 24,
n = 59;month 36, n = 62. aBMD, areal bonemineral density; DXA, dual-energyx-ray absorptiometry;MIAF,Medical Image Analysis Framework; QCT, quantitative computed tomography;
vBMD, volumetric bone mineral density.
Fig. 3. QCT MIAF vBMD percentage changes from baseline in total hip compartments.
A. Trabecular compartment. B. Subcortical compartment. C. Cortical compartment.
Least-squaresmeans, 95% conﬁdence intervals (CIs), and p-values from analysis of covari-
ancemodel are presented. ⁎p b 0.05 comparedwith baseline and placebo; †p b 0.05 com-
pared with baseline; ‡p b 0.0001 compared with month 12. Month 12, n = 60; month 24,
n = 59; month 36, n = 62. MIAF, Medical Image Analysis Framework; QCT, quantitative
computed tomography; vBMD, volumetric bone mineral density.
485H.K. Genant et al. / Bone 56 (2013) 482–488compartments. In the denosumab group atmonth 12, BMC increased by
4.1% in the trabecular compartment, 2.3% in the subcortical compart-
ment, and 2.2% in the cortical compartment (p b 0.001 for all). Gains
also were observed in all 3 compartments at month 24 (7.2%, 3.9%,
and 3.2%, respectively; p b 0.05 for all) and month 36 (8.4%, 4.9%, and
3.9%, respectively; p b 0.001 for all; Fig. 4). Outer and inner cortical
regions also had signiﬁcant gains from baseline and placebo (data not
shown).
Observed absolute changes in vBMD and BMC for integral and com-
partmental assessments also were signiﬁcant in the denosumab group
compared with the placebo group (p b 0.0001 for all), with larger abso-
lute changes in the cortical compartment than the trabecular or subcor-
tical compartments (Figs. 4A and B). The absolute increases from
baseline observed in hip BMC atmonth 36were 247 mg in the trabecu-
lar compartment, 108 mg in the subcortical compartment, and 456 mg
in the cortical compartment in the denosumab-treated group.
Discussion
We undertook this analysis to further characterize compartmental
changes associated with the observed improvements in aBMD previ-
ously documented by DXA with denosumab treatment at the total hip,
in the context of the signiﬁcant hip fracture reductions observed in
the FREEDOMstudy [20].MIAF provides amore comprehensivemethod
to evaluate integral and compartment changes from QCT scans, includ-
ing measuring changes within subregions of the cortex, evaluating the
subcortical region, and quantifying cortical geometry.
In this QCT MIAF substudy from FREEDOM, signiﬁcant and progres-
sive increases in total hip integral vBMD and BMC were conﬁrmed to
result from signiﬁcant corresponding gains across trabecular and cor-
tical compartments at months 12, 24, and 36. The results extend the
previously observed aBMD increases from other phase 2 and phase 3
denosumab clinical trials that have measured bone mass using DXA
[18–21]. The positive effect of denosumab on total hip integral vBMD
and BMC is consistent with a recently reported study using MINDWAYS
to analyze QCT scans [25]. However, results for the cortical compart-
ment differ as the MINDWAYS analysis showed large increases with
denosumab in cortical BMC and volume, but surprisingly not in cor-
tical BMD, suggesting that the increase in BMC was largely caused by
an increase in cortical volume [25]. The MIAF analysis showed similar
percentage changes for vBMD and BMC across all bone compartments
indicating that volumes, in particular cortical volume, did not change
substantially. This difference with respect to the MINDWAYS analysis
is explained by the difference in segmentation approaches. Indeed, sim-
ulations explained that with a global threshold, as used byMINDWAYS,
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486 H.K. Genant et al. / Bone 56 (2013) 482–488a longitudinal change in cortical BMD resulted in an artiﬁcial change in
cortical volume, and therefore an exaggeration of the change in cortical
BMC relative to the change in cortical BMD.
Gains also were observed in the subcortical (transitional) com-
partment, a region also relevant to bone strength, and which may
represent remnants of eroded cortical bone, the trabecular–cortical
boundary, and/or cortical bone that has become “trabecularized”
from endocortical and intracortical resorption. The absolute changes
in cortical vBMD and BMC in subjects treated with denosumab were
noteworthy and larger than those observed in the trabecular compart-
ment. While both increases in trabecular and cortical vBMD and BMC
are important to improve bone strength, the large gain in the cortical
region, which was similar in the outer and inner regions of the corticalshell, is of particular signiﬁcance to older patients with osteoporosis
who may have already lost substantial trabecular bone, or in whom
the trabecular structures in the bone have become disconnected, and
are at increased risk for fracture. In these individuals, their higher frac-
ture risk and decreased hip strength have been attributed to signiﬁcant
deﬁcits in the cortical shell [28–30]. Thus, protecting and improving the
cortical compartment may be paramount to observe fracture reduction
in the elderly population. Supporting this observation is the report that
denosumab signiﬁcantly reduced the risk of hip fractures in subjects
aged ≥75 years by 62% (95% CI, 22%, 82%). This observed hip fracture
incidence in the denosumab-treated older subjects was similar to that
of untreated subjects b75 years in whom hip fractures are a less fre-
quent event [31].
487H.K. Genant et al. / Bone 56 (2013) 482–488The data reported here therefore provide more accurate insight
on the effects of denosumab on trabecular, subcortical, and cortical
bone compartments, and the possible relationships to fracture re-
ductions. In FREEDOM, improvements in total hip aBMD observed
with denosumab treatment accounted for approximately 80% of the
nonvertebral fracture risk reduction [24], and this robust relation-
ship suggested that the gains in mass with denosumab treatment were
achieved across all compartments, a hypothesis now documented in
this study.
This study also highlights the value of evaluating absolute change, in
addition to percentage change, when documenting changes over time
with QCT. Indeed, previous reporting of percentage change rather than
absolute change may have obscured our understanding of the impact
of therapies on different bone compartments and their possible contri-
butions to fracture risk reductions. Percentage changes in both vBMD
and BMC in the denosumab-treated subjects were larger in the trabecu-
lar compartment than in the cortical compartment, but assessment of
absolute changes revealed that larger gains in vBMD and BMCwere ob-
served in the cortical compartment. The absolute increases in vBMDand
BMCwere also noteworthy in the subcortical compartment, particularly
because those increases occurred in a signiﬁcantly smaller subcortical
volume compared with the trabecular and cortical volumes. The appar-
ent discrepancy between percentage and absolute changes is explained
by the fact that vBMD in the trabecular compartment is lower because of
the large inter-trabecular spaces and the low density of the surrounding
fatty bone marrow. While it is informative to differentiate percentage
and absolute changes, as well as vBMD and BMC changes, it remains
to be determined, which has the greatest inﬂuence on biomechanical
strength. Nevertheless, this study supports the use of techniques other
than DXA in the evaluation of changes in response to therapy to better
understand their impact on fracture risk reductions.
There are recognized technical limitations of the QCT technique,
in particular partial volume artifacts in the cortical regions, which are
caused by the limited spatial resolution of about 500 μm in-plane and
1 to 1.25 mm slice thickness, and overall beam hardening effects,
which can inﬂuence themeasurements [32]. The analysis also is limited
by the small numbers of subjects, although QCT studies reporting on the
effect of other therapies have been typically of this size or smaller
[33–35]. Finally, as QCT was only performed in a subset of FREEDOM
participants, it is not possible to relate QCT changes to fracture events
in the overall FREEDOM study, and results of sub-VOIs of the total hip,
such as femoral neck, trochanter, or intertrochanter within the total
hip, were not detailed in this study. Notwithstanding these limitations,
this study advances our understanding of bone compartmental changes
in response to denosumab treatment and their potential contributions
to observed improved strength, which was previously reported for the
same subset of subjects [36], and to the robust hip fracture reductions
observed in FREEDOM in those patients at increased or high risk for
fracture [20].
Conclusion
Denosumab treatment was associated with progressive improve-
ments in bone density and mass at the hip over the 36-month duration
of the FREEDOM study. These improvements were documented in the
trabecular, subcortical, and cortical compartments. Denosumab offers a
valuable therapeutic option to signiﬁcantly increase bone mass at the
hip to reduce hip fracture risk in postmenopausal womenwith osteopo-
rosis at increased or high risk for fracture.
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